Airuini® is the domestic commercial brand name of Pyrotinib Maleate Tablets, an oral irreversible pan-HER tyrosine kinase inhibitor independently developed by Jiangsu Hengrui Pharmaceuticals. It inhibits EGFR, HER2 and HER4 simultaneously, blocks downstream oncogenic signaling pathways, and suppresses proliferation of…
AiRuiKa® is the commercial brand name of Camrelizumab for Injection, a humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody independently developed by Jiangsu Hengrui Pharmaceuticals. It binds to the PD-1 receptor on T lymphocytes, blocks its binding to PD-L1/PD-L2 on tumor…
HIBRUKA® is the international commercial brand name of Orelabrutinib Tablets, an orally active, irreversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Innocare. It covalently binds to BTK, inhibiting B-cell receptor signaling and thereby suppressing the proliferation and survival of malignant…
Tyvyt® is the commercial brand name of Sintilimab Injection, a fully human anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Innovent Biologics and Eli Lilly. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2 to…
Symbiox® is the commercial brand name of Benvitimod Cream, a topical immunomodulatory agent developed by Sino Biopharmaceutical. It acts as a selective inhibitor of the phosphodiesterase 4 (PDE4) enzyme, reducing pro-inflammatory cytokine production and inflammation in the skin. Main IndicationsTopical…
RYZNEUTA® is the commercial brand name of Efbemalenograstim Alfa Injection, a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) analog developed by Yisheng Biopharma. It stimulates the proliferation and differentiation of neutrophil progenitor cells in the bone marrow, thereby increasing peripheral…
Anniko® is the commercial brand name of Penpulimab Injection, a humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by CTTQ Sunccine Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…
Etesevimab is a humanized anti-SARS-CoV-2 neutralizing monoclonal antibody, co-developed by Eli Lilly and Company and Junshi Biosciences. It binds to the spike protein of SARS-CoV-2, blocking viral attachment and entry into host cells. It is authorized for use in combination…
Cejemly® is the commercial brand name of Sugemalimab Injection, a fully human anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody developed by CStone Pharmaceuticals and Pfizer. It binds to PD-L1 expressed on tumor cells and immune cells, blocking its interaction with…
Hansizhuang® is the commercial brand name of Serplulimab Injection, a recombinant humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Henlius Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…